Drug Trial Radar · NCT03875729
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
328
Actual
Start
Apr 5, 2019
Primary completion
May 1, 2023
Study completion May 1, 2023
Sponsor
- Lead sponsor
- Provention Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 8 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.. Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.
Conditions
- Type 1 Diabetes Mellitus
Interventions
teplizumabBiological
Treatment
PlaceboBiological
Control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT)Time frame: Baseline to Week 78
Locations
62 sites in 9 countries. Site status is shown where the registry gives one.
Rady Children's Hospital-San Diego (Site 004)
San Diego, California
UCSF Medical Center (Site 001)
San Francisco, California
Diablo Clinical Research, Inc. (Site 002)
Walnut Creek, California
University of Colorado-Barbara Davis Center for Childhood Diabetes (Site 005)
Aurora, Colorado
Yale University of Medicine (Site 020)
New Haven, Connecticut
UF Clinical and Translation Research Building (Site 015)
Gainesville, Florida
Nemours Children's Specialty Care-Endocrinology (Site 047)
Jacksonville, Florida
University of Miami Health System (Site 028)
Miami, Florida
All Children's Hospital-Johns Hopkins Medicine (Site 048)
St. Petersburg, Florida
University of South Florida Diabetes and Endocrinology Center (Site 011)
Tampa, Florida
Atlanta Diabetes Associates (Site 009)
Atlanta, Georgia
Centricity Research (Site 006)
Columbus, Georgia
St. Luke's Children's Endocrinology (Site 052)
Boise, Idaho
Rocky Mountain Diabetes and Osteoporosis Center (Site 007)
Idaho Falls, Idaho
University of Chicago Medical Center (Site 017)
Chicago, Illinois
Indiana University Hospital and Riley Hospital for Children (Site 014)
Indianapolis, Indiana
U. Iowa Children's Hospital (Site 023)
Iowa City, Iowa
Capital Diabetes & Endocrine Associates (Site 029)
Camp Springs, Maryland
Baystate Pediatric Endocrinology & Diabetes (Site 040)
Springfield, Massachusetts
U. Minnesota Health Clinical Research Unit (Site 031)
Minneapolis, Minnesota
Children's Mercy Hospitals & Clinics (Site 026)
Kansas City, Missouri
Washington University School of Medicine (Site 018)
St Louis, Missouri
Women and Children's Hospital of Buffalo (Site 010)
Buffalo, New York
UNC Hospitals Children's Specialty Clinic (Site 038)
Chapel Hill, North Carolina
Rainbow Babies & Children's Hospital (Site 049)
Cleveland, Ohio
Cleveland Clinic (Site 051)
Cleveland, Ohio
Endocrinology Service Northwest, LLC (Site 034)
Bend, Oregon
Childrens Hospital of Philadelphia - Endocrinology (Site 021)
Philadelphia, Pennsylvania
Sanford Diabetes and Thyroiid Clinical (Site 013)
Sioux Falls, South Dakota
AM Diabetes & Endocrinology Center (Site 008)
Bartlett, Tennessee
Vanderbilt University Medical Center (Site 024)
Nashville, Tennessee
Children's Medical Center Dallas (Site 033)
Dallas, Texas
Benaroya Research Institute at Virginia Mason (Site 016)
Seattle, Washington
MultiCare Institute for Research & Innovation (Site 003)
Tacoma, Washington
CHU UCL Namur, site Clinique Sainte-Elisabeth (Site 205)
Namur, Belgium
UZ Brussel - Campus Jette (Site 202)
Brussels, Brussels Capital, Belgium
UZ Gent (Site 206)
Ghent, Oost-Vlaanderen, Belgium
Alberta Diabetes Institute Clinical Research Unit Li Ka Shing Centre for Health Research Innovation (Site 103)
Edmonton, Alberta, Canada
BC Diabetes (Site 102)
Vancouver, British Columbia, Canada
Montreal Children's Hospital-McGill (Site 101)
Montreal, Quebec, Canada
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.